See the highlights from our 2018 California Life Sciences Industry Report and learn how the Golden State leads the world in life sciences innovation, educating thousands of new scientists, attracting billions in public and private investment, employing thousands and producing hundreds of new therapies and technologies to improve patient care.
CLSA Pres. & CEO Sara Radcliffe pens an op-ed in the Los Angeles Daily News outlining the strength of California life sciences industry, and calling on policymakers and stakeholders to sustain and nurture its growth.
David Beier of the VC firm Bay City Capital, pens an op-ed in the San Francisco Chronicle outlining the flaws of Senate Bill 17.
CLSA’s latest Protect Access & Innovation piece highlights an LA Times article regarding insurance industry practices that limit patient access to care.
CLSA’s latest Protect Access & Innovation flyer calls attention to a recent op-ed in The Hill (“The man behind the curtain in drug price increases”) by Rep. Earl Carter, the only pharmacist serving in Congress, highlighting the roles that PBMs play in the drug pricing equation.
CLSA’s latest Protect Access & Innovation flyer calls attention to a recent “I Am Essential” patient advocate coalition letter, calling on HHS Secretary Sylvia Mathews Burwell to more aggressively enforce the Affordable Care Act’s prohibition on discriminatory treatment of patients, particularly those with chronic conditions.
See the highlights from our 2017 California Life Sciences Industry Report. California leads the world in life sciences innovation. Premier research institutions combine with a unique entrepreneurial spirit to develop new technologies, attract investors and push the state’s economy to greater heights.
The Feds are gunning for the biggest middle man in the American pharmaceutical game, Express Scripts, according to government filings published on Tuesday along with the company’s earnings.
The health law prohibits insurers from discriminating against people with serious illnesses, but some marketplace plans sidestep that taboo by making the drugs that people with HIV need unavailable or unaffordable, complaints filed recently with the Department of Health and Human Services’ Office for Civil Rights allege.
Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen. However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.